<?xml version="1.0" encoding="UTF-8"?> <!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd"> <ArticleSet> <Article> <Journal> <PublisherName>njbms</PublisherName> <JournalTitle>NJBMS</JournalTitle> <PISSN>0976-6626</PISSN> <EISSN>2455-1740</EISSN> <Volume-Issue>Volume 10 Issue 3</Volume-Issue> <PartNumber/> <IssueTopic>Multidisciplinary</IssueTopic> <IssueLanguage>English</IssueLanguage> <Season>January - March 2020</Season> <SpecialIssue>N</SpecialIssue> <SupplementaryIssue>N</SupplementaryIssue> <IssueOA>Y</IssueOA> <PubDate> <Year>-0001</Year> <Month>11</Month> <Day>30</Day> </PubDate> <ArticleType>Pharmacology</ArticleType> <ArticleTitle>A Comparative Study On Efficacy And Safety Of Amlodipine And Cilnidipine In The Treatment Of Mild To Moderate Essential Hypertension.</ArticleTitle> <SubTitle/> <ArticleLanguage>English</ArticleLanguage> <ArticleOA>Y</ArticleOA> <FirstPage>112</FirstPage> <LastPage>123</LastPage> <AuthorList> <Author> <FirstName>Shajahan .O</FirstName> <LastName>.M</LastName> <AuthorLanguage>English</AuthorLanguage> <Affiliation/> <CorrespondingAuthor>N</CorrespondingAuthor> <ORCID/> <FirstName>Rajaram</FirstName> <LastName>.S</LastName> <AuthorLanguage>English</AuthorLanguage> <Affiliation/> <CorrespondingAuthor>Y</CorrespondingAuthor> <ORCID/> <FirstName>Ramya. R</FirstName> <LastName/> <AuthorLanguage>English</AuthorLanguage> <Affiliation/> <CorrespondingAuthor>Y</CorrespondingAuthor> <ORCID/> <FirstName>S. R. Ranga</FirstName> <LastName>Bhashyam</LastName> <AuthorLanguage>English</AuthorLanguage> <Affiliation/> <CorrespondingAuthor>Y</CorrespondingAuthor> <ORCID/> </Author> </AuthorList> <DOI>10.31975/NJBMS.2020.10035</DOI> <Abstract>BACKGROUND: Calcium channel blockers are one of the first line drugs used in the treatment of newly diagnosed case of primary essential hypertension. Cilnidipine is a new calcium channel blocker which acts on both L and N-type of calcium channel unlike Amlodipine which acts only on L-type calcium channels. Hence this study was done to compare the efficacy and safety of amlodipine and cilnidipine in patients with essential hypertension.METHODS: 60 patients with newly diagnosed essential hypertension were enrolled for the study. They were randomly assigned to Amlodipine (N=30) and Cilnidipine (N=30) groups. Amlodipine 5mg and Cilnidipine 10 mg was given once daily for a period of 60 days.RESULT: After 60 days of treatment the mean systolic blood pressure was 120.80±1.45 and 120 mmHg(p=0.004).and the mean diastolic pressure was 80.33±0.92 and 80mmHg (p=0.052) respectively for Amlodipine and Cilnidipine group. There was a reduction in heart rate for patients treated with cilnidipine. In the second visit 7(23%) patient treated with amlodipine presented with ankle edema which was highly significant (p=0.014). There was significant reduction in both systolic and diastolic blood pressure in first and second visit for both Amlodipine and Cilnidipine group. Adverse events were less, and tolerability was better with Cilnidipine.CONCLUSION: Novel calcium channel blocker Cilnidipine with its activity on both L-and N-type calcium channel could be beneficial than Amlodipine that blocks only L-type calcium channel in terms of tolerability and safety.</Abstract> <AbstractLanguage>English</AbstractLanguage> <Keywords>Hypertension; L- and N-type calcium channel blocker; Cilnidipine.</Keywords> <URLs> <Abstract>https://njbms.in/ubijournal-v1copy/journals/abstract.php?article_id=7436&title=A Comparative Study On Efficacy And Safety Of Amlodipine And Cilnidipine In The Treatment Of Mild To Moderate Essential Hypertension.</Abstract> </URLs> <References> <ReferencesarticleTitle>References</ReferencesarticleTitle> <ReferencesfirstPage>16</ReferencesfirstPage> <ReferenceslastPage>19</ReferenceslastPage> <References/> </References> </Journal> </Article> </ArticleSet>